Allworth Financial LP Acquires New Shares in Halozyme Therapeutics, Inc. $HALO

Key Points

• Allworth Financial initiated a 37,664-share position in Halozyme Therapeutics valued at approximately $2.95 million, while other institutions also established new stakes. Institutional investors collectively own 97.79% of HALO’s outstanding shares.
• Halozyme insiders sold 64,103 shares worth approximately $5.23 million over the past 90 days, including sales by CEO Helen Torley and Director Mahesh Krishnan, both conducted under pre-arranged Rule 10b5-1 plans.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $91.20. The company recently exceeded quarterly earnings and revenue expectations, reporting $2.28 EPS and $481 million in revenue, up 47.7% year over year.

Allworth Financial LP bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 37,664 shares of the biopharmaceutical company's stock, valued at approximately $2,948,000.

Several other institutional investors have also recently bought and sold shares of HALO. Silvant Capital Management LLC bought a new stake in shares of Halozyme Therapeutics during the second quarter worth $56,000. PCM Encore LLC acquired a new stake in Halozyme Therapeutics in the second quarter valued at $256,000. Vise Technologies Inc. bought a new position in Halozyme Therapeutics during the 2nd quarter worth $743,000. E Fund Management Co. Ltd. bought a new position in Halozyme Therapeutics during the 2nd quarter worth $455,000. Finally, Aurora Investment Counsel acquired a new position in Halozyme Therapeutics during the 2nd quarter worth about $1,427,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company's stock, valued at $79,987,320.40. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the business's stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the sale, the director owned 14,462 shares in the company, valued at $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 64,103 shares of company stock worth $5,226,496 over the last ninety days. 2.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

HALO has been the subject of several recent research reports. Benchmark reissued a "buy" rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. HC Wainwright lifted their price objective on Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Citizens Jmp upped their target price on Halozyme Therapeutics from $92.00 to $93.00 and gave the company a "market outperform" rating in a report on Friday, August 7th. UBS Group reissued a "buy" rating and set a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Finally, Wells Fargo & Company raised their price target on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an "equal weight" rating in a report on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $91.20.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $108.17 on Friday. The company has a market cap of $12.28 billion, a PE ratio of 32.29, a P/E/G ratio of 0.43 and a beta of 0.85. Halozyme Therapeutics, Inc. has a fifty-two week low of $61.22 and a fifty-two week high of $108.49. The firm has a 50-day simple moving average of $83.19 and a 200 day simple moving average of $73.74. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm had revenue of $481.00 million for the quarter, compared to analysts' expectations of $402.28 million. During the same quarter last year, the company posted $1.54 earnings per share. Halozyme Therapeutics's revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source